FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667043> ?p ?o ?g. }

• W4385667043 endingPage "e2134963" @default.
• W4385667043 startingPage "e2134963" @default.
• W4385667043 abstract "Background: Pediatric-inspired protocols with prospective monitoring of minimal residual disease (MRD) are considered the standard of intensive treatment for adults with acute lymphoblastic leukemia (ALL). They have been used in the Czech Republic since 2007. Aims: To evaluate treatment outcomes of adult patients with ALL treated at five hematology centers between 2007–2020 according to the GMALL 07/2003 and ALL CELL Junior 2012 protocols. The analysis is retrospective. Methods: Two hundred and ninety-seven patients aged 18–65 years were treated. The Ph-negative cohort consisted of 203 patients with a median age 36 years (range 18–64 years) of which 140 (69.0 %) had BCP-ALL and 63 (31.0%) T-ALL. Ninety patients (44.8%) were classified as standard risk and 104 (51.7 %) as high risk according to GMALL definitions. The Ph-positive group consisted of 94 subjects with a median age 45 years (range 19–65 years). Results: In the Ph-negative cohort, 189 (93.1%) patients achieved complete remission, 5 (2.4%) patients were refractory, and early mortality was 3.0%. Seventy (34.5%) patients experienced relapse in a median of 10.6 months. Survival at 3 and 5 years was 63.5% and 55.9% for overall survival (OS) and 54.5% and 49.7% for disease-free survival (DFS), respectively. Young adults under 35 years of age (P = 0.015), patients without initial CNS infiltration (P = 0.016), with MRD negativity before consolidation treatment (P < 0.001), transplanted in the 1st complete remission (P < 0.001), and subjects treated after 2012 (P = 0.05) had significantly better overall survival. In a multivariate analysis, MRD at week 11 was the only independent factor affecting OS (HR 3.06; P = 0.006). For DFS, baseline CNS infiltration (HR 2.08; P = 0.038) and MRD at week 11 (HR 2.15; P = 0.020) were significant. There was no significant difference in OS between patients who achieved MRD negativity at week 11 and were or were not transplanted (median not reached in both groups). This contrasted with the survival of patients with persistent MRD at week 11 and subsequent allogeneic stem cell transplantation (HSCT) (median OS 62.1 months) and patients with persistent MRD at week 11 without HSCT (median OS 20.1 months). In the Ph-positive cohort, 84 (89.4%) patients achieved complete remission, 1 (1.0%) patient was refractory, early mortality was 4.3%. Twenty-six (27.7%) patients relapsed in a median of 8.6 months. Survival at 3 and 5 years was 57.2% and 52.4% for OS and 50.2% and 44.9% for DFS, respectively. Transplanted patients and patients diagnosed after 2012 had statistically better overall survival (P < 0.001). Summary/Conclusion: The introduction of pediatric-inspired protocols with treatment intensification according to MRD levels resulted in a significant improvement in the survival outcomes of adult patients with ALL. Keywords: Therapy, Minimal residual disease (MRD), Acute lymphoblastic leukemia" @default.
• W4385667043 created "2023-08-09" @default.
• W4385667043 creator A5013216901 @default.
• W4385667043 creator A5013446879 @default.
• W4385667043 creator A5042672780 @default.
• W4385667043 creator A5044586150 @default.
• W4385667043 creator A5049209624 @default.
• W4385667043 creator A5064262892 @default.
• W4385667043 creator A5065448452 @default.
• W4385667043 creator A5067390651 @default.
• W4385667043 creator A5068854434 @default.
• W4385667043 date "2023-08-01" @default.
• W4385667043 modified "2023-09-26" @default.
• W4385667043 title "P388: THERAPY OF ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON PEDIATRIC-INSPIRED PROTOCOLS IN THE CZECH REPUBLIC IN 2007–2020" @default.
• W4385667043 doi "https://doi.org/10.1097/01.hs9.0000968460.21349.63" @default.
• W4385667043 hasPublicationYear "2023" @default.
• W4385667043 type Work @default.
• W4385667043 citedByCount "0" @default.
• W4385667043 crossrefType "journal-article" @default.
• W4385667043 hasAuthorship W4385667043A5013216901 @default.
• W4385667043 hasAuthorship W4385667043A5013446879 @default.
• W4385667043 hasAuthorship W4385667043A5042672780 @default.
• W4385667043 hasAuthorship W4385667043A5044586150 @default.
• W4385667043 hasAuthorship W4385667043A5049209624 @default.
• W4385667043 hasAuthorship W4385667043A5064262892 @default.
• W4385667043 hasAuthorship W4385667043A5065448452 @default.
• W4385667043 hasAuthorship W4385667043A5067390651 @default.
• W4385667043 hasAuthorship W4385667043A5068854434 @default.
• W4385667043 hasBestOaLocation W43856670431 @default.
• W4385667043 hasConcept C121332964 @default.
• W4385667043 hasConcept C126322002 @default.
• W4385667043 hasConcept C141071460 @default.
• W4385667043 hasConcept C142424586 @default.
• W4385667043 hasConcept C167135981 @default.
• W4385667043 hasConcept C187212893 @default.
• W4385667043 hasConcept C205545832 @default.
• W4385667043 hasConcept C2776694085 @default.
• W4385667043 hasConcept C2778461978 @default.
• W4385667043 hasConcept C2779823535 @default.
• W4385667043 hasConcept C2909962599 @default.
• W4385667043 hasConcept C3018657049 @default.
• W4385667043 hasConcept C71924100 @default.
• W4385667043 hasConcept C72563966 @default.
• W4385667043 hasConcept C87355193 @default.
• W4385667043 hasConceptScore W4385667043C121332964 @default.
• W4385667043 hasConceptScore W4385667043C126322002 @default.
• W4385667043 hasConceptScore W4385667043C141071460 @default.
• W4385667043 hasConceptScore W4385667043C142424586 @default.
• W4385667043 hasConceptScore W4385667043C167135981 @default.
• W4385667043 hasConceptScore W4385667043C187212893 @default.
• W4385667043 hasConceptScore W4385667043C205545832 @default.
• W4385667043 hasConceptScore W4385667043C2776694085 @default.
• W4385667043 hasConceptScore W4385667043C2778461978 @default.
• W4385667043 hasConceptScore W4385667043C2779823535 @default.
• W4385667043 hasConceptScore W4385667043C2909962599 @default.
• W4385667043 hasConceptScore W4385667043C3018657049 @default.
• W4385667043 hasConceptScore W4385667043C71924100 @default.
• W4385667043 hasConceptScore W4385667043C72563966 @default.
• W4385667043 hasConceptScore W4385667043C87355193 @default.
• W4385667043 hasIssue "S3" @default.
• W4385667043 hasLocation W43856670431 @default.
• W4385667043 hasLocation W43856670432 @default.
• W4385667043 hasOpenAccess W4385667043 @default.
• W4385667043 hasPrimaryLocation W43856670431 @default.
• W4385667043 hasRelatedWork W1597579779 @default.
• W4385667043 hasRelatedWork W2022129113 @default.
• W4385667043 hasRelatedWork W2381530651 @default.
• W4385667043 hasRelatedWork W2410504739 @default.
• W4385667043 hasRelatedWork W2412346639 @default.
• W4385667043 hasRelatedWork W2560635697 @default.
• W4385667043 hasRelatedWork W2953985085 @default.
• W4385667043 hasRelatedWork W4246925039 @default.
• W4385667043 hasRelatedWork W4247941550 @default.
• W4385667043 hasRelatedWork W4367600461 @default.
• W4385667043 hasVolume "7" @default.
• W4385667043 isParatext "false" @default.
• W4385667043 isRetracted "false" @default.
• W4385667043 workType "article" @default.